What did we learn about tocilizumab use against COVID-19? A single-center observational study from an intensive care unit in Serbia

BACKGROUND: Selection of effective and safe therapy for management of patients with coronavirus disease is challenging. Tocilizumab (TZB) has emerged as a potential treatment option for COVID-19. Several aspects regarding Tocilizumab treatment remain uncertain, such as the optimal timing for its adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Adzic-Vukicevic, Tatjana, Markovic, Dejan, Reljic, Aleksandar, Brkovic, Voin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683091/
https://www.ncbi.nlm.nih.gov/pubmed/38034537
http://dx.doi.org/10.3389/fmed.2023.1253135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683091/
https://www.ncbi.nlm.nih.gov/pubmed/38034537
http://dx.doi.org/10.3389/fmed.2023.1253135

Ejemplares similares